As per Market Research Future Analysis, the Global Porcine Vaccines Market was valued at USD 1.79 Billion in 2023 and is projected to grow to USD 3.04 Billion by 2032, with a CAGR of 5.27% from 2024 to 2032. The market is driven by the increasing prevalence of swine diseases, advancements in vaccine technology, and government initiatives supporting vaccine development. Key players like Boehringer Ingelheim and Ceva Santé Animale are introducing innovative vaccines to enhance swine health management. The Americas is expected to dominate the market due to a high number of pig farms and rising swine diseases, while the Asia-Pacific region is anticipated to be the fastest-growing market due to supportive government initiatives and growth opportunities for manufacturers.
Key trends influencing the porcine vaccines market include technological advancements and increased disease prevalence.
Bayer AG, Boehringer Ingelheim International GmbH, Ceva Santé Animale, Merck & Co., Inc., Zoetis, Inc.
June 2024: Boehringer Ingelheim has introduced the Ingelvac® PRRSFLEX vaccine, an advanced adjuvant technology designed to enhance immune response and provide extended protection against multiple PRRS virus strains, offering improved efficacy and safety in field conditions.
January 2024:Ceva Santé Animale has introduced the Vaxxitek® HVT+IBR marker vaccine for swine, providing protection against PRRS and other common porcine diseases. The vaccine uses a recombinant virus vector platform, enhancing herd health management and vaccine technology advancement.
The porcine vaccine denotes an administrative and clinical drug that helps improve swine health. These vaccines help to protect from pathogens, deadly viruses and bacteria. Due to vaccines, widespread diseases such as swine influenza, diarrhoea, and respiratory syndrome have been reduced.
The increase in the commonness of diseases in swine all over the globe acts as one of the main factors which are operating the growth of the porcine vaccines market. The continuous invention in the market to fulfil the customer demand and the rise in initiatives by the government to support stages of development of vaccines increase the market growth. The increasing focus on delivering vaccination services to properly use the swine vaccines to deal with bacteria or viruses further influences market growth.
Moreover, the technological development, rise in population and increase in the number of generic drug producers positively impact the porcine vaccines market. Furthermore, the special designation from the regulatory authority extends profitable opportunities to the main market players in the predicted period of 2022 to 2029. The covid-19 pandemic had an important impact on the market. Considering this global challenge, the pharmaceutical industry has extended its research at an extraordinary pace. For example, the research and development unit of Boehringer Ingelheim Animal Health business was renamed Animal Health Global Innovation.
It was given a new administrative structure based on disease and a system-centred R&D approach. This allows the company to bring modernisations in treatment and preventive veterinary therapies to the market.
The porcine vaccines market has been segmented into type, disease indication, and end user.
By type, the market has been segmented into Inactivated vaccines, Live attenuated vaccines, Toxoid vaccines, Recombinant vaccines, Conjugate vaccines, DNA vaccines.
On the basis of disease indication, the market has been segmented into PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), Swine influenza, Aujeszky's disease (AD), Porcine Circovirus Associated Disease (PCVAD) and others.
The market, by end user, has been segmented into Veterinary Hospitals and Hog Production Farm.
The porcine vaccines market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The porcine vaccines market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European porcine vaccines market has been segmented into Western Europe and Eastern Europe. The Western Europe porcine vaccines market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The porcine vaccines market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The porcine vaccines market in the Middle East & Africa has been segmented into the Middle East and Africa.
Geographically, the Americas is anticipated to dominate the global porcine vaccines market owing to the rise in number of pig farms and rise in swine diseases such as PED (Porcine Epidemic Diarrhea), PRRS (Porcine Reproductive & Respiratory Syndrome), swine influenza etc. Moreover, rapid increase in contract farming and independent farming for pig cultivation is driving the growth of this market in this region. According to a report from National Hog Farmer, there were 71.7 million pigs in US hog farms as of June 2016.
Europe is expected to hold the second largest position in the global porcine vaccines market. The market growth in this region is attributed to increasing number of production units for swine and high consumption of pork meat.
The porcine vaccines market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to initiatives by various government agencies, animal associations, and high growth opportunities for major key players for setting up their vaccine manufacturing plants in this region.
The Middle East & Africa has the lowest share of the global porcine market. Majority of the market of the region is anticipated to be held by the Middle East region owing to the growing government initiatives for the animal care sector.
In the year 2021
The vaccine was created together and manufactured using CrisBio. This improved the rate of vaccine sales in the market.
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 1.79 Billion |
| Market Size 2024 | USD 1.92 Billion |
| Market Size 2032 | USD 3.04 Billion |
| CAGR | 5.27% |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Disease indication, and End user |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Bayer AG, Bimeda, Inc., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Eli Lilly and Company, Merck & Co. Inc., Sanofi S.A., Vetoquinol S.A.,Zoetis, Inc., PBS Animal Health, Aptimmune |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers | · Rising number of biotechnology companies · Research organizations engaged in research and development of porcine vaccines · Government initiatives for funding agriculture and animal husbandry sector · Rising demand for porcine meat and gelatine |
Porcine Vaccines Market Highlights:
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
